Vistin Pharma ASA Total Assets
Vistin Pharma ASA total assets. Based on the latest financial reports, Vistin Pharma ASA (VISTN) holds total assets worth Nkr453.56 Million NOK (≈ $47.73 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Vistin Pharma ASA for the company's overall valuation and market capitalisation.
Total Assets of Vistin Pharma ASA (2016–2025)
Total assets of Vistin Pharma ASA from 2016 to 2025. This chart illustrates how Vistin Pharma ASA's total assets have evolved over time, based on quarterly financial data. See Vistin Pharma ASA share price for real-time trading data and today's change.
Vistin Pharma ASA - Asset Composition Analysis
Vistin Pharma ASA Total Assets Breakdown (December 2025)
Vistin Pharma ASA total assets breakdown as of December 2025. Vistin Pharma ASA's total assets of Nkr453.56 Million consist of 46.3% current assets and 53.7% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 3.7% |
| Accounts Receivable | Nkr89.71 Million | 20.4% |
| Inventory | Nkr82.13 Million | 18.7% |
| Property, Plant & Equipment | Nkr0.00 | 0.0% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Vistin Pharma ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Vistin Pharma ASA (VISTN) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vistin Pharma ASA's current assets represent 46.3% of total assets in 2025, a decrease from 80.8% in 2016.
- Cash Position: Cash and equivalents constituted 3.7% of total assets in 2025, down from 28.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 20.4% of total assets.
Vistin Pharma ASA Competitors by Total Assets
Key competitors of Vistin Pharma ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Vistin Pharma ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.96 | 2.69 | 5.25 |
| Quick Ratio | 1.83 | 1.47 | 4.30 |
| Cash Ratio | 0.00 | 0.20 | 0.00 |
| Working Capital | Nkr144.02 Million | Nkr106.54 Million | Nkr118.32 Million |
Vistin Pharma ASA - Advanced Valuation Insights
This section examines the relationship between Vistin Pharma ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.52 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | 14.2% |
| Total Assets | Nkr439.43 Million |
| Market Capitalization | $85.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vistin Pharma ASA's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Vistin Pharma ASA's assets grew by 14.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vistin Pharma ASA (2016–2025)
The table below shows the annual total assets of Vistin Pharma ASA from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr439.43 Million ≈ $46.24 Million |
+14.15% |
| 2024-12-31 | Nkr384.94 Million ≈ $40.51 Million |
-4.57% |
| 2023-12-31 | Nkr403.40 Million ≈ $42.45 Million |
-0.94% |
| 2022-12-31 | Nkr407.21 Million ≈ $42.85 Million |
+22.23% |
| 2021-12-31 | Nkr333.15 Million ≈ $35.06 Million |
+3.49% |
| 2020-12-31 | Nkr321.92 Million ≈ $33.87 Million |
-36.15% |
| 2019-12-31 | Nkr504.17 Million ≈ $53.05 Million |
+0.82% |
| 2018-12-31 | Nkr500.06 Million ≈ $52.62 Million |
+115.78% |
| 2017-12-31 | Nkr231.75 Million ≈ $24.39 Million |
-17.09% |
| 2016-12-31 | Nkr279.52 Million ≈ $29.41 Million |
-- |
About Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is… Read more